Importance of the surveillance program for hepatocellular carcinoma in patients wich liver cirrosis
Keywords:
hepatocellular carcinoma, liver cirrhosis, surveillance programAbstract
Introduction: Hepatocellular carcinoma represents an important health problem. Its main risk factor is liver cirrhosis and in most patients it is detected in late stages. The surveillance program in these patients can favor early diagnosis.
Objective: Determine the staging of hepatocellular carcinoma at the time of diagnosis and relate it to permanence in a surveillance program.
Material and methods: A descriptive, retrospective, cross-sectional study was carried out in 44 patients with a confirmed diagnosis of hepatocellular carcinoma between 2020 - 2023 in the CIMEQ. The main variables of the study were: etiology of liver cirrhosis; form of hepatocellular carcinoma debut, prognostic evaluation according to Barcelona Clinic Liver Cancer and permanence in a surveillance program. Descriptive measures of summary, percentage, standard deviation and Chi square were used.
Results: The most common etiology was viral cirrhosis in 22 patients (56 %). In 21 (47.7 %) the form of hepatocellular carcinoma debut was the finding by ultrasound, followed by the complications of cirrhosis (34.1%); 16 patients (36.4%) were found in the initial stage (A) of Barcelona Clinic Liver Cancer, followed by intermediate (B) and advanced (C) stages and of the 26 patients (59.1 %) who were not in a surveillance program, 8 were in stage B and 12 in C, with a predominance of advanced stage, with a significant difference between the two groups (p≤0.01).
Conclusions: The hepatocellular carcinoma surveillance program in cirrhotic patients allows early diagnosis and can favor prognosis.
References
Ferlay J, Colombet M, Soerjomataram I, Parkin D, Pineros M, Znaor A, et al. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021. DOI: https://doi.org/10.1002/ijc.33588.
Tunissiolli N, Castanhole M, Biselli P, Pavarino É, da Silva R, Goloni E. Hepatocellular carcinoma: A comprehensive review of biomarkers, clinical aspects, and therapy. Asian Pacific Journal of Cancer Prevention. 2017;18(4): 863-872. DOI: https://doi.org/10.22034/APJCP.2017.18.4.863.
Akinyemiju T, Abera S, Ahmed M, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional and national level: Results from the global burden of disease study 2015. JAMA Oncol.2017;3(12):1683–1691. DOI: https://doi.org/10.1001%2Fjamaoncol.2017.3055
Rumgay H, Arnold M, Ferlay J, Lesi O, Cabasag C,Vignat J, Laversanne M,McGlynn K,Soerjomataram I. Global Prediction of primary liver cáncer in 2020 and predictions to 2040. JHepatol.2022; 77(6): 1598-1606.DOI: https://doi.org/10.1016/j.jhep.2022.08.021
Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. DOI:https://doi.org/10.3322/caac.21660
Goossens N, Hoshida Y. Tratamiento personalizado del carcinoma hepatocelular basado en información molecular: perspectivas futuras. Clin Liver Dis(Hoboken).2016; 8 (1): 43-48.DOI: https://doi.org/10.1002/cld.601
Pascual S, Herrera I, Irurzun J. Et al. New advances in hepatocellular carcinoma. World J Hepatol. 2016; 8(9): 421-438. DOI: https://doi.org/10.4254%2Fwjh.v8.i9.421.
Meshram R, Kathwate G, Gacche R. Progress, evolving therapeutic/diagnostic approaches, and challenges in the management of hepatitis C virus infections. Arch Virol [Internet].2022 [citado 2024 Feb 25];167(3):717-736. Disponible en: https://link.springer.com/article/10.1007/s00705-02205375-0
Anstee Q, Reeves, H, Kotsiliti, E., Govaere, O, Heikenwalder M. From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol. 2019;16, 411–428.DOI: https://doi.org/10.1038/s41575-019-0145-7.
Kanwal F, Kramer J, Mapakshi S, Natarajan Y, Chayanupatkul M, Richardson P, et al. Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease. Gastroenterology. 2018; 155: 1828-1837. DOI: https://doi.org/10.1053/j.gastro.2018.08.024
Anuario Estadístico de Salud. 2021 [citado 2024 Feb 25]. Disponible en: http://bvscuba.sld.cu/anuario-estadistico-de-cuba/
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018; 69 (1):182-236.DOI: https://doi.org/10.1016/j.jhep.2018.03.019
Singal A, Llovet J, Yarchoan M, Mehta N, Heimbach J, Dawson L, et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023; 78:1922–1965. DOI: https://doi.org/10.1097/HEP.0000000000000466
Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet 2018; 391:1301-1314. DOI: https://doi.org/10.1016/S0140-6736(18)30010-2
Castellanos M, López Y, Sánchez Y, Lazo S, Hernández J. Particularidades del carcinoma hepatocelular en los pacientes con cirrosis hepática. Revista Cubanade Medicina 2011 [citado 2024 Feb 25]:50(1): 57-69.disponible en: https://scielo.sld.cu/scielo.php?pid=S0034-7523201100001000006&script=sci-arttext
Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681-693. DOI:https://doi.org:10.1016/j.jhep.2021.11.018
Yang J, Hainaut P, Gores G, Amadou A, Plymoth A, Roberts L. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019; 16(10):589-604. DOI: https://doi.org/10.1038%2Fs41575-019-0186-y
Marín J, Vergara J, Cajiao L, Arroyave D, Castro S, Ceballos L, Muñoz O, Díaz G. Characterization, management and prognosis of a cohort of cirrhotic patients with hepatocellular carcinoma. Pablo Tobón Uribe Hospital 2012-2018. Hepatología. 2020; 1:134-144.DOI: http://dx.doi.org/10.52784/27112330.121
Park J, Chen M, Colombo M, Roberts L, Schwartz M, Chen P, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int.2015; 35:2155-2166. DOI: https://doi.org/10.1111/liv.12818
Pok S, Barn V, Wong H, Blackburn A, Board P, Farell G, Teoh N. Testosterone regulation of cyclin E kinase: a key factor in determining gender differences in hepatocarcinogenesis. J Gastroenterol Hepatol. 2016; 31(6):1210-1219. DOI: https://doi.org./10.1111/jgh.13232
McGlynn K, Petrick J, El-Serag H. Epidemiology of Hepatocellular Carcinoma. Hepatology. 2021;73(1):4-13. DOI: https://doi.org./10.1002/hep.31288
Fassio E, Díaz S, Santa C, Reig M, Martínez Y, Alves A, et al. Etiology of hepatocellular carcinoma in Latin America: a prospective, multicenter,international study. Ann Hepatol. 2010; 9(1):63–9. DOI: https://doi.org/10.1016/S1665-2681(19)31681-3
Hernández J, Samada M, Roque A, Cruz Y, Howland I, Fernández I. Diagnostic value of alpha-fetoprotein for hepatocellular carcinoma. Biotecnol Apl [Internet]. 2011 Mar [citado 2024 Feb 25] ; 28(1): 34-39. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1027-28522011000100005&lng=es
Huang D, El-Serag H, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021; 18(4):223-38. https://doi.org./10.1038/s41575-020-00381-6
Moreno J. Actualización en hepatología y gastroenterología. España 2016, p 1551-1560.Disponible en: https://www/libreriaproteo.com/libro/ver/1849480.&=%
Llovet J, Zucman J, Pikarsky E, Sangro B, Schwartz M, Herman M, Gores G. Hepatocellular carcinoma.Nat Rev Dis Primers. 2021; 7(1). DOI: https://doi.org./10.1038/s41572-020-00240-3
Sarasin F, Giostra E, Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. Am J Med 1996; 101(4):422-434.DOI: https://doi.org./10.1016/S0002-9343(96)00197-0
Singal A, Tiro J, Li X, Adams B, Chubak J. Hepatocellular carcinoma surveillance among patients with cirrhosis in a population based integrated healthcare delivery system. J Clin Gastrol. 2017; 51(7): 650-655.DOI: https://doi.org/10.1097%2FMCG.0000000000000708
Simmons O, Feng Y,Parikh N, Singal A. Primary care provider practice patterns and barriers to hepatocellular carcinoma surveillance Clin Gastroenterol Hepatol.2019; 17(4): 766-773. DOI: https://doi.org./10.1016/j.cgh.2018.07.029
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Kenia Valenzuela Aguilera, Marcia Samada Suárez, Julio César Hernández Perera, Sheyla Moret Vara, Alejandro Roque Valdés, José Antonio Jordán González
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The authors retain copyright and all unrestricted publication rights.
Medicoquirúrgicas Research is licensed under the Creative Commons Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0) and follows the SciELO Publishing Schema (SciELO PS) for publishing in XML format.
You are free to:
- Share — copy and redistribute the material in any medium or format.
- Adapt — remix, transform, and build upon the material.
The license cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do this in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
Non-Commercial — You may not use the material for commercial purposes.
No Additional Restrictions — You may not apply legal terms or technological measures that legally restrict others from making any use permitted by the license.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where their use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all the permissions you need for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
